EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice

Pavel A Solopov, Ruben Manuel Luciano Colunga Biancatelli, Tierney Day, Betsy Gregory, Elizabeth R Sharlow, John S Lazo, John D Catravas

The Journal of Pharmacology and Experimental Therapeutics · 2025-03 · 392 (3) · 100022

DOI: 10.1124/jpet.124.002154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-03. Verfasst von Pavel A Solopov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia. Electronic address: psolopov@odu.edu. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, National Heart Lung and Blood Institute Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Acute lung injuryAcute respiratory distress syndromeCoronavirus disease 2019KVX-053Spike protein

Autor:innen und Institutionen

  • Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia. Electronic address: psolopov@odu.edu.
  • Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia.
  • Department of Pharmacology, School of Medicine, University of Virginia, Charlottesville, Virginia; KeViRx Inc, Charlottesville, Virginia.
  • Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia; School of Medical Diagnostic & Translational Sciences, College of Health Sciences, Old Dominion University, Norfolk, Virginia.

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Heart Lung and Blood Institute Division of Intramural Research

Zitieren

APA

Solopov, P. A., Colunga Biancatelli, R. M. L., Day, T., Gregory, B., Sharlow, E. R., Lazo, J. S., & Catravas, J. D. (2025). KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice. The Journal of Pharmacology and Experimental Therapeutics, 392(3), 100022. https://doi.org/10.1124/jpet.124.002154

Vancouver

Solopov PA, Colunga Biancatelli RML, Day T, Gregory B, Sharlow ER, Lazo JS, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(3):100022. doi:10.1124/jpet.124.002154

BibTeX
@article{Solopov2025,
  author = {Solopov, Pavel A and Colunga Biancatelli, Ruben Manuel Luciano and Day, Tierney and Gregory, Betsy and Sharlow, Elizabeth R and Lazo, John S and Catravas, John D},
  title = {KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  volume = {392},
  number = {3},
  pages = {100022},
  doi = {10.1124/jpet.124.002154}
}
Kostenlos starten →